Take­da pulls dengue vac­cine ap­pli­ca­tion af­ter FDA re­quests more da­ta

Take­da has with­drawn an FDA ap­pli­ca­tion for its dengue vac­cine can­di­date fol­low­ing a re­quest by reg­u­la­tors for more da­ta.

The Japan­ese biotech filed a bi­o­log­ics li­cense ap­pli­ca­tion for TAK-003 last year, an­nounc­ing in No­vem­ber that it scored pri­or­i­ty re­view sta­tus, which typ­i­cal­ly short­ens the FDA’s de­ci­sion-mak­ing process to six months. On Tues­day, how­ev­er, the com­pa­ny re­vealed that it vol­un­tar­i­ly pulled the BLA af­ter reg­u­la­tors “sought ad­di­tion­al da­ta not cap­tured with­in the TAK-003 clin­i­cal tri­al pro­to­col,” which the agency had pre­vi­ous­ly re­viewed and ac­cept­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER